BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28185577)

  • 1. Artificial neural network classifier predicts neuroblastoma patients' outcome.
    Cangelosi D; Pelassa S; Morini M; Conte M; Bosco MC; Eva A; Sementa AR; Varesio L
    BMC Bioinformatics; 2016 Nov; 17(Suppl 12):347. PubMed ID: 28185577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Attribute Driven Incremental Discretization and Logic Learning Machine to build a prognostic classifier for neuroblastoma patients.
    Cangelosi D; Muselli M; Parodi S; Blengio F; Becherini P; Versteeg R; Conte M; Varesio L
    BMC Bioinformatics; 2014; 15 Suppl 5(Suppl 5):S4. PubMed ID: 25078098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.
    Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L
    BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients.
    Cangelosi D; Blengio F; Versteeg R; Eggert A; Garaventa A; Gambini C; Conte M; Eva A; Muselli M; Varesio L
    BMC Bioinformatics; 2013; 14 Suppl 7(Suppl 7):S12. PubMed ID: 23815266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients.
    Fardin P; Barla A; Mosci S; Rosasco L; Verri A; Versteeg R; Caron HN; Molenaar JJ; Ora I; Eva A; Puppo M; Varesio L
    Mol Cancer; 2010 Jul; 9():185. PubMed ID: 20624283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
    De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
    Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.
    Applebaum MA; Jha AR; Kao C; Hernandez KM; DeWane G; Salwen HR; Chlenski A; Dobratic M; Mariani CJ; Godley LA; Prabhakar N; White K; Stranger BE; Cohn SL
    Oncotarget; 2016 Nov; 7(47):76816-76826. PubMed ID: 27765905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer.
    Fjeldbo CS; Julin CH; Lando M; Forsberg MF; Aarnes EK; Alsner J; Kristensen GB; Malinen E; Lyng H
    Clin Cancer Res; 2016 Aug; 22(16):4067-76. PubMed ID: 27012812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.
    De Preter K; Mestdagh P; Vermeulen J; Zeka F; Naranjo A; Bray I; Castel V; Chen C; Drozynska E; Eggert A; Hogarty MD; Izycka-Swieszewska E; London WB; Noguera R; Piqueras M; Bryan K; Schowe B; van Sluis P; Molenaar JJ; Schramm A; Schulte JH; Stallings RL; Versteeg R; Laureys G; Van Roy N; Speleman F; Vandesompele J
    Clin Cancer Res; 2011 Dec; 17(24):7684-92. PubMed ID: 22031095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.
    Formicola D; Petrosino G; Lasorsa VA; Pignataro P; Cimmino F; Vetrella S; Longo L; Tonini GP; Oberthuer A; Iolascon A; Fischer M; Capasso M
    J Transl Med; 2016 May; 14(1):142. PubMed ID: 27188717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated cross-platform prognosis study on neuroblastoma patients.
    Chen QR; Song YK; Wei JS; Bilke S; Asgharzadeh S; Seeger RC; Khan J
    Genomics; 2008 Oct; 92(4):195-203. PubMed ID: 18598751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
    Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
    Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined analysis of RNA-sequence and microarray data reveals effective metabolism-based prognostic signature for neuroblastoma.
    Meng X; Feng C; Fang E; Feng J; Zhao X
    J Cell Mol Med; 2020 Sep; 24(18):10367-10381. PubMed ID: 32683778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A five-gene signature derived from m6A regulators to improve prognosis prediction of neuroblastoma.
    Wang Z; Cheng H; Xu H; Yu X; Sui D
    Cancer Biomark; 2020; 28(3):275-284. PubMed ID: 32176634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming.
    Cangelosi D; Morini M; Zanardi N; Sementa AR; Muselli M; Conte M; Garaventa A; Pfeffer U; Bosco MC; Varesio L; Eva A
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.
    Xie Y; Xu H; Fang F; Li Z; Zhou H; Pan J; Guo W; Zhu X; Wang J; Wu Y
    Am J Surg Pathol; 2018 Aug; 42(8):1027-1035. PubMed ID: 29794872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A signature of 29 immune-related genes pairs to predict prognosis in patients with neuroblastoma.
    Song J; Zhao Q; Xu Y; Zhu L
    Int Immunopharmacol; 2020 Nov; 88():106994. PubMed ID: 33182060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors.
    Axelson H; Fredlund E; Ovenberger M; Landberg G; Påhlman S
    Semin Cell Dev Biol; 2005; 16(4-5):554-63. PubMed ID: 16144692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients.
    Nevo I; Oberthuer A; Botzer E; Sagi-Assif O; Maman S; Pasmanik-Chor M; Kariv N; Fischer M; Yron I; Witz IP
    Int J Cancer; 2010 Apr; 126(7):1570-81. PubMed ID: 19739072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.